Announcement • Jul 14
Paltac Corporation(TSE:8283) dropped from FTSE All-World Index (USD) Paltac Corporation(TSE:8283) dropped from FTSE All-World Index (USD) Live News • Jul 10
MEDIPAL Acquisition Tightens Grip on Paltac After Tender Offer Completion MEDIPAL HOLDINGS CORPORATION has completed a tender offer for Paltac’s Tokyo Stock Exchange-listed common shares, increasing its ownership stake and tightening its control over Paltac’s governance and strategic direction.
The transaction underlines Paltac’s role within MEDIPAL’s group structure and could influence how consumer and healthcare products are distributed across Japan, given Paltac’s position in that supply chain.
Paltac shares trade at ¥6,680.00, with the stock up 40.0% over the past 90 days, indicating that recent trading has been strong around the time of this change in control.
With greater control by MEDIPAL, future decisions on capital allocation, business priorities and integration with the wider group are more likely to align with MEDIPAL’s objectives. This can concentrate both execution risk and potential benefits for Paltac shareholders. Announcement • Jul 08
MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders. MediPal Holdings Corporation (TSE:7459) proposed to acquire remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders for approximately ¥190 billion on May 8, 2026. A cash consideration of ¥192.46 billion valued at ¥6650 per share will be paid by MediPal Holdings Corporation. As part of consideration, ¥192.46 billion is paid towards common equity of Paltac Corporation. Upon completion, MediPal Holdings Corporation will hold 100% stake of Paltac Corporation. The transaction will be funded by means of loans from Mizuho Bank, Ltd. As of June 19, 2026, S.T. Corporation has resolved to tender its 339,000 shares.
The transaction is subject to minimum tender. The Board of Directors of Paltac Corporation formed a special committee for the transaction. The expected completion of the transaction is on July 7, 2026.
Nishimura & Asahi acted as legal advisor for MediPal Holdings Corporation. Nomura Securities Co., Ltd. acted as financial advisor for MediPal Holdings Corporation. Oh-Ebashi LPC & Partners acted as legal advisor for Paltac Corporation. Daiwa Securities Co. Ltd. acted as financial advisor for Paltac Corporation. Anderson Mori & Tomotsune acted as legal advisor for Paltac Corporation. Plutus Consulting Co., Ltd. acted as financial advisor and fairness opinion provider for Paltac Corporation.
MediPal Holdings Corporation (TSE:7459) completed the acquisition of remaining 47.60% stake in Paltac Corporation (TSE:8283) from group of shareholders on July 7, 2026. A total of 24,466,104 shares were tendered, which was above the minimum number of shares to be purchased (8,676,100 shares). MediPal Holdings Corporation plans to implement a series of procedures to make the Tender Offeror the sole shareholder of Paltac Corporation (the “Squeeze-out Procedures”). Upon completion, the shares of Paltac Corporation will be delisted from the Prime Market of the Tokyo Stock Exchange. 
